Slowing chronic renal failure progression: an update;Ralentissement de la progression de la maladie rénale chronique : actualités

Nephrologie et Therapeutique

Volumn 3, Issue SUPPL. 4, 2007, Pages 206-213

  Esnault, V ^a  

^a PASTEUR HOSPITAL   (France)

Author keywords

Albuminuria; Angiotensin converting enzyme inhibitor; Angiotensin receptor blocker; Anti aldosterone; Chronic renal failure; Diuretic; Progression; Proteinuria; Renin angiotensin system

Indexed keywords

ALISKIREN; ALLOPURINOL; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; CANDESARTAN; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN A RECEPTOR ANTAGONIST; EPLERENONE; ERYTHROPOIETIN; FUROSEMIDE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; PENTOXIFYLLINE; PIRFENIDONE; PLACEBO; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; VALSARTAN; VITAMIN D;

ARTICLE; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; MICROALBUMINURIA; PATHOPHYSIOLOGY; PREDICTION; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 38949087884     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1769-7255(07)78748-5     Document Type: Article

References (53)

1. Jafar T.H., Stark P.C., Schmid C.H., Landa M., Maschio G., de Jong P.E., et al. Progression of chronic kidney disease : the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition : a patient-level meta-analysis. Ann Intern Med 139 (2003) 244-252
2. Hou F.F., Zhang X., Zhang G.H., Xie D., Chen P.Y., Zhang W.R., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354 (2006) 131-140
3. Li P.K., Chow K.M., Wong T.Y., Leung C.B., and Szeto C.C. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 139 (2003) 105-112
4. de Zeeuw D., Remuzzi G., Parving H.H., Keane W.F., Zhang Z., Shahinfar S., et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65 (2004) 2309-2320
5. Doulton T.W., He F.J., and MacGregor G.A. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45 (2005) 880-886
6. Stergiou G.S., Skeva I.I., Baibas N.M., Roussias L.G., Kalkana C.B., Achimastos A.D., et al. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angioten-sin-receptor antagonism in essential hypertension. J Car-diovasc Pharmacol 35 (2000) 937-941
7. Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 59 (2001) 2282-2289
8. Berger E.D., Bader B.D., Ebert C., Risler T., and Erley C.M. Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition. J Hypertens 20 (2002) 739-743
9. Rossing K., Christensen P.K., Jensen B.R., and Parving H.H. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 25 (2002) 95-100
10. Rossing K., Jacobsen P., Pietraszek L., and Parving H.H. Renopro-tective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 26 (2003) 2268-2274
11. Jacobsen P., Andersen S., Rossing K., Hansen B.V., and Parving H.H. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 17 (2002) 1019-1024
12. Jacobsen P., Andersen S., Rossing K., Jensen B.R., and Parving H.H. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 63 (2003) 1874-1880
13. Mogensen C.E., Neldam S., Tikkanen I., Oren S., Viskoper R., Watts R.W., et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Bmj 321 (2000) 1440-1444
14. Azizi M., Linhart A., Alexander J., Goldberg A., Menten J., Sweet C., et al. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens 18 (2000) 1139-1147
15. Ferrari P., Marti H.P., Pfister M., and Frey F.J. Additive antiprotei-nuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 20 (2002) 125-130
16. Jacobsen P., Andersen S., Jensen B.R., and Parving H.H. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 14 (2003) 992-999
17. Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., and Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE) : a randomised controlled trial. Lancet 361 (2003) 117-124
18. Morgan T., Anderson A., Bertram D., and MacInnis R.J. Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. J Renin Angiotensin Aldosterone Syst 5 (2004) 64-71
19. Weir M.R., Smith D.H., Neutel J.M., and Bedigian M.P. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens 14 (2001) 665-671
20. Kuriyama S., Tomonari H., Tokudome G., Horiguchi M., Hayashi H., Kobayashi H., et al. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens Res 25 (2002) 849-855
21. Kincaid-Smith P., Fairley K., and Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 17 (2002) 597-601
22. Tutuncu N.B., Gurlek A., and Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetol 38 (2001) 157-161
23. Segura J., Praga M., Campo C., Rodicio J.L., and Ruilope L.M. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. J Renin Angiotensin Aldosterone Syst 4 (2003) 43-47
24. Horita Y., Tadokoro M., Taura K., Suyama N., Taguchi T., Miyazaki M., et al. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy. Hypertens Res 27 (2004) 963-970
25. Matos J.P., de Lourdes Rodrigues M., Ismerim V.L., Boasquevisque E.M., Genelhu V., and Francischetti E.A. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy. Clin Nephrol 64 (2005) 180-189
26. Ruilope L.M., Aldigier J.C., Ponticelli C., Oddou-Stock P., Bot-teri F., and Mann J.F. Safetyof the combination of valsartan and benazepril in patients with chronic renal disease European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 18 (2000) 89-95
27. Russo D., Minutolo R., Pisani A., Esposito R., Signoriello G., Andreucci M., et al. Coadministration of losartan and enal-april exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 38 (2001) 18-25
28. Campbell R., Sangalli F., Perticucci E., Aros C., Viscarra C., Perna A., et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 63 (2003) 1094-1103
29. Esnault V.L., Ekhlas A., Delcroix C., Moutel M.G., and Nguyen J.M. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 16 (2005) 474-481
30. Buter H., Hemmelder M.H., Navis G., de Jong P.E., and de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlo-rothiazide. Nephrol Dial Transplant 13 (1998) 1682-1685
31. van de Wal R.M., Gansevoort R.T., van der Harst P., Boomsma F., Thijs Plokker H.W., van Veldhuisen D.J., et al. Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondia-betic patients. Hypertension 48 (2006) 870-876
32. Bellizzi V., Di Iorio B.R., De Nicola L., Minutolo R., Zamboli P., Trucillo P., et al. Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney Int 71 (2007) 245-251
33. Esnault V.L., Ekhlas A., and Nguyen J.M. An increase in diuretic dosage on top of ACEI and ARB dual blockade better decrease proteinuria than up titration of combined ACEI and ARB. J Am Soc Nephrol 17 (2006) 804A
34. Rossing K., Schjoedt K.J., Smidt U.M., Boomsma F., and Parving H.H. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 28 (2005) 2106-2112
35. Schjoedt K.J., Rossing K., Juhl T.R., Boomsma F., Tarnow L., Rossing P., et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 70 (2006) 536-542
36. Bianchi S., Bigazzi R., and Campese V.M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 70 (2006) 2116-2123
37. White W.B., Duprez D., St Hillaire R., Krause S., Roniker B., Kuse-Hamilton J., et al. Effects of the selective aldoste-rone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41 (2003) 1021-1026
38. Pitt B., Reichek N., Willenbrock R., Zannad F., Phillips R.A., Roniker B., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventri-cular hypertrophy study. Circulation 108 (2003) 1831-1838
39. Williams G.H., Burgess E., Kolloch R.E., Ruilope L.M., Nie-gowska J., Kipnes M.S., et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 93 (2004) 990-996
40. Rachmani R., Slavachevsky I., Amit M., Levi Z., Kedar Y., Berla M., et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 21 (2004) 471-475
41. Chrysostomou A., Pedagogos E., MacGregor L., and Becker G.J. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 1 (2006) 256-262
42. Rossing K., Schjoedt K.J., Jensen B.R., Boomsma F., and Parving H.H. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbu-minuria. Kidney Int 68 (2005) 1190-1198
43. Schmieder R.E., Klingbeil A.U., Fleischmann E.H., Veelken R., and Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 16 (2005) 3038-3045
44. Hollenberg K., Parving H.H., Viberti G., and Remuzzi G. The Dio-van Reduction of Proteinuria (DROP) study: albuminuria response to high-doses of valsartan in type 2 diabetes mel-litus. J Am Soc Nephrol 17 (2006) 158A
45. Aranda P., Segura J., Ruilope L.M., Aranda F.J., Frutos M.A., Lopez V., et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondi-abetic nephropathies. Am J Kidney Dis 46 (2005) 1074-1079
46. Hermida R.C., Calvo C., Ayala D.E., and Lopez J.E. Decrease in uri-nary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension 46 (2005) 960-968
47. Sandhu S., Wiebe N., Fried L.F., and Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17 (2006) 2006-2016
48. Douglas K., O'Malley P.G., and Jackson J.L. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 145 (2006) 117-124
49. Sarafidis P.A., and Bakris G.L. Protection of the kidney by thia-zolidinediones: an assessment from bench to bedside. Kidney Int 70 (2006) 1223-1233
50. Agarwal R., Acharya M., Tian J., Hippensteel R.L., Melnick J.Z., Qiu P., et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68 (2005) 2823-2828
51. Siu Y.P., Leung K.T., Tong M.K., and Kwan T.H. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47 (2006) 51-59
52. Navarro J.F., Mora C., Muros M., and Garcia J. Additive antipro-teinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol 16 (2005) 2119-2126
53. Gouva C., Nikolopoulos P., Ioannidis J.P., and Siamopoulos K.C. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 66 (2004) 753-760